Open Access
| Issue |
BIO Web Conf.
Volume 214, 2026
The 2025 International Conference on Biomedical, Bioinformatics and Statistics (ICBBS 2025)
|
|
|---|---|---|
| Article Number | 01020 | |
| Number of page(s) | 5 | |
| Section | Biomedical, Bioinformatics and Statistics | |
| DOI | https://doi.org/10.1051/bioconf/202621401020 | |
| Published online | 02 February 2026 | |
- Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A.. Cancer statistics,. CA: A Cancer Journal for Clinicians, [online] 73(1), pp.17–48. (2023) [Google Scholar]
- Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J.S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K.P. and Gandara, D.. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26(21), pp. 3543–3551. (2008) [Google Scholar]
- Mok, T.S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.-J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A. and Fukuoka, M.. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, [online] 361(10), pp. 947–957. (2009) [Google Scholar]
- Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., Carcereny, E., Ahn, M.-J., Felip, E., Lee, J.-S., Hellmann, M.D., Hamid, O., Goldman, J.W., Soria, J.-C., Dolled-Filhart, M. and Rutledge, R.Z.. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. New England Journal of Medicine, [online] 372(21), pp.-. (2015) [Google Scholar]
- Levantini, E., Maroni, G., Del Re, M. and Tenen, D.G.. EGFR Signaling Pathway as Therapeutic Target in Human Cancers. Seminars in Cancer Biology, 85, pp.253–275. (2022) [Google Scholar]
- Paez, J.G.. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 304(5676), pp.1497–1500. (2004) [Google Scholar]
- Zhang, X., Gureasko, J., Shen, K., Cole, P.A. and Kuriyan, J.. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor. Cell, 125(6), pp. 1137–1149. (2006) [Google Scholar]
- Hirsch, F.R., Varella-Garcia, M., Bunn, P.A., Di Maria, M.V., Veve, R., Bremnes, R.M., Baron, A.E., Zeng, C. and Franklin, W.A.. Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. Journal of Clinical Oncology, 21(20), pp. 3798–3807. (2003) [Google Scholar]
- Tang, X., Marileila Varella-Garcia, Xavier, A.C., Massarelli, E., Ozburn, N., Moran, C. and Wistuba, I.I.. Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas. Cancer Prevention Research, [online] 1(3), pp.192–200. (2008) [Google Scholar]
- Han, F., He, J., Li, F., Yang, J., Wei, J., Cho, W.C. and Liu, X.. Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer. BioMed research international, (1), pp.1–10. (2015) [Google Scholar]
- Gazdar, A.F. and Minna, J.D.. Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops. Cancer Prevention Research, 1(3), pp.156–160. (2008) [Google Scholar]
- Burotto, M., Chiou, V.L., Lee, J.-M. and Kohn, E.C.. The MAPK pathway across different malignancies: A new perspective. Cancer, [online] 120(22), pp.3446–3456. (2014) [Google Scholar]
- Mayer, I.A. and Arteaga, C.L.. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review of Medicine, 67(1), pp.11–28. (2016) [Google Scholar]
- Villarino, A.V., Kanno, Y. and O'Shea, J.J.. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nature Immunology, 18(4), pp.374–384. (2017) [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.